The HSP90AA1 Knockout HEK293T Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population engineered for targeted disruption of the HSP90AA1 gene in the human embryonic kidney HEK293T cell line. This loss-of-function model abrogates expression of the inducible molecular chaperone HSP90??, enabling systematic investigation of chaperone-dependent cellular processes. The polyclonal format ensures retention of genetic heterogeneity, avoiding biases associated with clonal selection while providing a robust platform for studying HSP90?? function across diverse cellular backgrounds. The editing process yields a heterogeneous knockout pool suitable for biochemical, cell-based, and pharmacological assays without the constraints of monoclonal derivation.
HEK293T cells are a widely utilized human embryonic kidney epithelial line stably expressing the SV40 large T antigen, which facilitates episomal replication of plasmids and significantly enhances transfection efficiency. This feature makes the cells a preferred host for protein expression, viral production, and signal transduction studies. Their renal epithelial origin provides a physiologically relevant context for analyzing chaperone-mediated processes in a human cell model, and their robust growth characteristics and ease of manipulation render them ideal for high-throughput genetic and pharmacological screens. The combination of HEK293T??s technical advantages with targeted HSP90AA1 knockout creates a versatile system for dissecting HSP90?? biology.
HSP90??, encoded by HSP90AA1, functions as a central hub in proteostasis, assisting the folding, maturation, and stability of a vast array of client proteins. It is transcriptionally activated by heat shock factor 1 (HSF1) and forms dynamic complexes with cochaperones such as HSP70, HOP (STIP1), p23 (PTGES3), AHA1 (AHSA1), and CDC37. Critical clients include the kinases AKT, RAF1, and EGFR, the cell cycle regulator CDK4, and transcription factor p53. Consequently, HSP90?? is integral to PI3K/AKT and MAPK/ERK signaling cascades, cell cycle progression, and apoptosis regulation. Knockout of HSP90AA1 disrupts this chaperone network, leading to misfolding, ubiquitination, and proteasomal degradation of key oncogenic and signaling proteins, thereby attenuating proliferative and survival signals.
In the HEK293T background, ablation of HSP90?? expression results in destabilization of multiple client proteins that are otherwise robustly expressed in this line, making the knockout cells a powerful tool for discerning HSP90??-dependent regulation of signal transduction. The high transfection efficiency of HEK293T cells allows for facile reintroduction of wild-type or mutant HSP90AA1 constructs, enabling structure-function studies and client interaction mapping. Furthermore, the SV40 large T antigen-driven immortalization provides a context in which HSP90????s role in cell cycle and stress responses can be dissected without the confounding effects of primary cell senescence, highlighting the model??s utility in cancer and chaperone biology research.
This polyclonal knockout product is particularly suited for applications such as validation of HSP90 inhibitors, investigation of client protein stability through western blotting and co-immunoprecipitation, and analysis of downstream signaling by phospho-AKT or phospho-ERK assays. It enables real-time assessment of cellular stress responses, apoptosis induction, and proliferation changes using viability and proteasome inhibition assays. The model also supports RT-qPCR-based verification of HSP90AA1 transcript disruption. By providing a genetically defined yet heterogeneous population, the cells facilitate robust, reproducible experiments in drug target validation and chaperone network dynamics. For additional information or technical support, please contact Ascent Research.
